(Q80542642)

English

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

scientific article published on 24 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

author name string

A Tefferi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

T L Lasho

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J Huang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C Finke

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

R A Mesa

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C Y Li

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

W Wu

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C A Hanson

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A Pardanani

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

24 January 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

756-761

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18216871%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405097

0 references

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405097

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80542642&oldid=1829721406"